New trials, publications, preprints and grants on this target, month by month.
Trial
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
1 May 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
CKM For Safe Use of SGLT2i in Type 1 Diabetes
1 Apr 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
1 Dec 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".
6 Nov 2026· Clinical and molecular hepatology· PUBMED
Publication
Direct cardiac or systemic? Reexamining the cardiovascular mechanisms of SGLT2 inhibitors and GLP-1 receptor agonists.
5 Nov 2026· Journal of basic and clinical physiology and pharmacology· PUBMED
Publication
Outcomes of SGLT2-inhibitor-induced euglycaemic diabetic ketoacidosis in a North Queensland intensive care unit: A retrospective cohort study.
5 Nov 2026· Anaesthesia and intensive care· PUBMED
Publication
Design principles for natural SGLT2 modulators from multi-scale computation.
4 Nov 2026· Royal Society open science· PUBMED
Publication
SGLT2 Inhibitors in Geriatric Heart Failure: Evidence, Safety, and Clinical Implementation.
3 Nov 2026· Current heart failure reports· PUBMED
Publication
Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes.
3 Nov 2026· The journal of prevention of Alzheimer's disease· PUBMED
Publication
Multi-organ proteomics identifies oxidative stress pathways underlying genetic and pharmacological SGLT2 suppression.
3 Nov 2026· Redox biology· PUBMED
Trial
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
2 Nov 2026· NA · RECRUITING· CTGOV
Publication
SGLT2 inhibitors in chronic kidney disease.
2 Nov 2026· Postgraduate medicine· PUBMED
Publication
Implications of SGLT2 Inhibitors, GLP-1RAs, and Nonsteroidal MRAs on the Anticipated Burden of Heart Failure.
2 Nov 2026· JACC. Heart failure· PUBMED
Publication
Influence of the PROFUND index on the effectiveness of SGLT2 inhibitors in elderly pluripathological patients with acute heart failure: PROFUND-IC registry.
2 Nov 2026· Medicina clinica· PUBMED
Publication
Real-World Comparison of Cardiorenal Outcomes With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes.
2 Nov 2026· Diabetes, obesity & metabolism· PUBMED
Trial
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts.
1 Nov 2026· Endocrinology, diabetes & metabolism· PUBMED
Publication
Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes.
1 Nov 2026· Endocrinology, diabetes & metabolism· PUBMED
Publication
Cardiovascular-kidney-metabolic syndrome: conceptual framework, clinical implications, and therapeutic perspectives with a focus on SGLT2 inhibitors.
1 Nov 2026· Postgraduate medicine· PUBMED
Publication
Challenge-Oriented Decision Tree for Analytical Method Selection in Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Triple Antidiabetic Fixed-Dose Combinations in Pharmaceutical Dosage Forms.
1 Nov 2026· Biomedical chromatography : BMC· PUBMED
Publication
Association of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.
1 Nov 2026· Current problems in cardiology· PUBMED
Publication
Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD.
31 Oct 2026· Diabetology international· PUBMED
Publication
SGLT2 inhibitor-induced genitourinary infections and the consequent antimicrobial-antidiabetic drug interactions: A narrative review of clinical and pharmacovigilance concern.
31 Oct 2026· Diabetes research and clinical practice· PUBMED
Publication
Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease.
30 Oct 2026· Journal of Alzheimer's disease : JAD· PUBMED
Publication
Haematological and iron-handling effects of SGLT2 inhibitors: a meta-analysis of randomised trials.
30 Oct 2026· Heart (British Cardiac Society)· PUBMED